NHS cancer waiting lists hit record high as treatment delays mount

More than 300,000 cancer patients in England are currently waiting longer than the NHS 62-day target from urgent GP referral to the start of treatment, according to the latest performance data published by NHS England — a figure that represents the worst backlog on record and one that senior clinicians warn is directly affecting patient survival outcomes. The crisis, compounding years of underfunding, workforce shortages, and pandemic-era disruption, has placed the United Kingdom's cancer care system under its most severe strain since the NHS was founded.

The 62-day standard, which requires patients to begin treatment within two months of an urgent cancer referral, has not been met nationally since the health service was forced to suspend elective care during the Covid-19 pandemic. However, data show the situation has continued to deteriorate well beyond the immediate post-pandemic recovery period, with performance now tracking at levels that health economists and oncologists describe as a structural, rather than temporary, failure. This follows months of growing concern detailed in our coverage of NHS cancer treatment delays hitting record highs, a pattern that shows no immediate sign of reversal.

The Scale of the Backlog

NHS England's monthly cancer waiting times statistics, which track performance against several key standards, paint a consistent picture of a system operating well below its own clinical thresholds. The 62-day target is considered the most clinically significant, as delays beyond this point have been directly correlated with worse survival rates for the most common cancer types, including breast, bowel, lung, and prostate cancer.

Which Tumour Types Are Most Affected?

Lung and gynaecological cancers have seen some of the most pronounced delays, according to NHS performance breakdowns. These cancers present particular diagnostic challenges — lung cancer, for instance, often requires multiple imaging and biopsy steps before a confirmed diagnosis enables treatment to begin. Haematological cancers, including leukaemia and lymphoma, have also been identified as areas of significant waiting-time pressure. Breast cancer pathways have performed comparatively better, partly due to dedicated screening infrastructure, but backlogs in diagnostic imaging capacity continue to create bottlenecks even in better-performing tumour streams. (Source: NHS England)

Regional Disparities Widen

Performance data show substantial variation between NHS trusts and integrated care systems. Some regions in the north of England and parts of the Midlands are recording 62-day performance figures below 60%, while a small number of trusts in less deprived areas continue to meet or approach the 85% standard. Health equity researchers have raised concern that geographic inequality in cancer outcomes — already well-documented — is likely to be amplified by uneven waiting-time performance. The NHS Long Term Plan committed to reducing cancer mortality and improving early diagnosis rates, but analysts note that the current backlog environment undermines the plan's core assumptions. (Source: NHS England; NHS Long Term Plan)

Why the Backlog Has Grown

The roots of the current crisis are multiple and interlocking. Pandemic disruption caused an estimated 40,000 fewer cancer diagnoses than expected in England during the peak lockdown periods, according to modelling published by Cancer Research UK and cited in Lancet Oncology. Many of those patients subsequently re-entered referral pathways with more advanced disease, increasing the complexity and length of treatment episodes and placing further strain on already-limited capacity.

Workforce Shortages Driving Delays

The NHS workforce crisis, explored in detail in our reporting on NHS waiting lists hitting record highs amid the staff crisis, is a primary structural driver of delayed cancer treatment. Shortfalls in oncologists, radiologists, histopathologists, and specialist cancer nurses create cascading delays at every stage of the diagnostic and treatment pathway. NHS data indicate there are currently thousands of unfilled consultant and nursing vacancies in cancer-related specialties across England. Radiotherapy capacity, in particular, has been identified as a critical constraint, with ageing linear accelerator equipment in some trusts and insufficient staffing to operate existing machines at full capacity. (Source: NHS England; NHS Workforce Statistics)

Diagnostic delays compound the treatment backlog. The volume of imaging — CT, MRI, PET, and endoscopy — required to investigate and stage cancer has grown substantially as clinical guidance has expanded the criteria for urgent referral. Endoscopy capacity across England remains insufficient to meet this demand, with waiting lists for upper and lower GI investigations running into months at many trusts. (Source: British Society of Gastroenterology; NHS England)

What the Evidence Says About Patient Outcomes

The clinical consequences of prolonged waiting times are well-established in peer-reviewed literature. A landmark study published in the BMJ found statistically significant associations between treatment delays and reduced overall survival across seven common cancer types. For colorectal cancer, delays beyond eight weeks from referral to treatment were associated with a 1.2 to 1.6 times higher risk of death at five years compared with patients treated within four weeks. For breast cancer, a four-week delay was associated with a 6% increase in the risk of death. (Source: BMJ)

Stage at Diagnosis: The Fundamental Challenge

Beyond individual treatment delays, clinicians and public health experts emphasise that the fundamental driver of poor cancer survival rates in the UK — compared with similarly wealthy nations — remains stage at diagnosis. England continues to diagnose a higher proportion of cancers at stages three and four than countries including Germany, Denmark, and Australia. NHS data show that while early diagnosis rates improved incrementally before the pandemic, recent years have seen that progress stall or reverse. Late-stage diagnosis is both a cause and a consequence of the backlog: patients presenting later require more intensive treatment, which itself consumes greater NHS capacity. (Source: NHS England; International Cancer Benchmarking Partnership)

The most recent data on 62-day performance, and its evolving trajectory, are tracked in ZenNewsUK's ongoing coverage — including our earlier analysis of NHS cancer waiting times hitting record highs — which documents the quarter-by-quarter deterioration in performance against national standards.

Government and NHS Response

NHS England and the Department of Health and Social Care have acknowledged the severity of the backlog and outlined a series of recovery measures. These include expanded use of community diagnostic centres — standalone facilities designed to increase diagnostic capacity outside hospital settings — and investment in additional radiotherapy equipment under a capital spending programme. The government has also pointed to the elective recovery fund and cancer-specific ring-fenced investment as evidence of commitment to addressing the backlog.

Critics, including the Royal College of Radiologists and Macmillan Cancer Support, argue that capital investment in equipment is insufficient without parallel investment in the clinical workforce to operate it. The Royal College of Radiologists has estimated that England needs several hundred additional clinical oncologists and clinical radiologists to meet current and projected demand. Training pipelines for these specialties span a minimum of eight to ten years, meaning workforce expansion cannot resolve short-term capacity deficits. (Source: Royal College of Radiologists; Macmillan Cancer Support)

Integrated Care Systems: A New Framework Under Pressure

The reorganisation of NHS commissioning into integrated care systems was intended, in part, to enable more coordinated cancer pathway management across provider organisations. However, health policy analysts note that ICSs are operating under considerable financial pressure, with many running significant deficits. Cancer waiting-time performance figures are now published at ICS level, increasing accountability, but accountability without additional resource is unlikely to drive meaningful improvement in the short term, officials have acknowledged. (Source: NHS England; Health Foundation)

What Patients Can Do

While systemic change is the primary lever for addressing the backlog, public health authorities and cancer charities continue to emphasise the importance of early presentation. NICE guidelines specify a range of symptoms that should trigger an urgent GP referral under the two-week-wait pathway. Awareness of these symptoms — and prompt presentation when they occur — remains one of the most significant individual-level factors in achieving an early-stage diagnosis.

• Unexplained or unintentional weight loss lasting more than a few weeks
• A lump, thickening, or swelling anywhere on the body that is new or changing
• Persistent cough, hoarseness, or a change in voice lasting more than three weeks
• Coughing or vomiting blood, or blood in urine or stools
• Persistent bloating, abdominal pain, or difficulty swallowing
• Unexplained fatigue that does not resolve with rest
• A sore or ulcer that does not heal within three weeks
• Any mole that is changing in size, shape, colour, or begins to bleed
• Night sweats that are persistent and unexplained
• Participation in national screening programmes — breast, bowel, and cervical — when invited

Patients who have been waiting beyond the 62-day standard are entitled to request information from their NHS trust about their position on the waiting list and the reasons for any delay. NHS England's patient advice services and voluntary organisations including Macmillan Cancer Support and Cancer Research UK provide guidance and support for those navigating prolonged diagnostic and treatment waits. (Source: NHS England; Macmillan Cancer Support; NICE)

The Outlook

Senior oncologists and health policy experts interviewed by specialist medical publications indicate that without a substantial and sustained increase in both workforce and infrastructure investment, the 62-day standard is unlikely to be consistently met within the current planning horizon. Some models suggest performance could deteriorate further before any improvement, as the cohort of patients whose cancers were not diagnosed during pandemic disruption continues to move through the treatment system presenting with more advanced disease.

For context on the sustained nature of this deterioration, our previous reporting on NHS cancer treatment delays reaching an 18-month high underlines that this is not a recent or sudden emergency, but an accelerating trend with deep structural causes. The NHS's ability to meet its own cancer waiting-time standards is now widely regarded as one of the most pressing tests of the health service's long-term viability as a comprehensive, universal system — and one whose resolution will require political commitment, not merely administrative reform.